Giuliani, S, Silva, AC, Borba, Joyce V. V. B., Ramos, PIP, Paveley, RA, Muratov, EN, Andrade, CH and Furnham, N. 2018. Computationally-guided drug repurposing enables the discovery of kinase targets and inhibitors as new schistosomicidal agents. [Online]. PLOS Computational Biology. Available from: https://doi.org/10.1371/journal.pcbi.1006515
Giuliani, S, Silva, AC, Borba, Joyce V. V. B., Ramos, PIP, Paveley, RA, Muratov, EN, Andrade, CH and Furnham, N. Computationally-guided drug repurposing enables the discovery of kinase targets and inhibitors as new schistosomicidal agents [Internet]. PLOS Computational Biology; 2018. Available from: https://doi.org/10.1371/journal.pcbi.1006515
Giuliani, S, Silva, AC, Borba, Joyce V. V. B., Ramos, PIP, Paveley, RA, Muratov, EN, Andrade, CH and Furnham, N (2018). Computationally-guided drug repurposing enables the discovery of kinase targets and inhibitors as new schistosomicidal agents. [Data Collection]. PLOS Computational Biology. https://doi.org/10.1371/journal.pcbi.1006515
Description
The development of novel therapeutics is urgently required for diseases where existing treatments are failing due to the emergence of resistance. This is particularly pertinent for parasitic infections of the tropics and sub-tropics, referred to collectively as neglected tropical diseases, where the commercial incentives to develop new drugs are weak. One such disease is schistosomiasis, a highly prevalent acute and chronic condition caused by a parasitic helminth infection, with three species of the genus Schistosoma infecting humans. Currently, a single 40-year old drug, praziquantel, is available to treat all infective species, but its use in mass drug administration is leading to signs of drug-resistance emerging. To meet the challenge of developing new therapeutics against this disease, we developed an innovative computational drug repurposing pipeline supported by phenotypic screening. The approach highlighted several protein kinases as interesting new biological targets for schistosomiasis as they play an essential role in many parasite’s biological processes. Focusing on this target class, we also report the first elucidation of the kinome of Schistosoma japonicum, as well as updated kinomes of S. mansoni and S. haematobium. In comparison with the human kinome, we explored these kinomes to identify potential targets of existing inhibitors which are unique to Schistosoma species, allowing us to identify novel targets and suggest approved drugs that might inhibit them. These include previously suggested schistosomicidal agents such as bosutinib, dasatinib, and imatinib as well as new inhibitors such as vandetanib, saracatinib, tideglusib, alvocidib, dinaciclib, and 22 newly identified targets such as CHK1, CDC2, WEE, PAKA, MEK1. Additionally, the primary and secondary targets in Schistosoma of those approved drugs are also suggested, allowing for the development of novel therapeutics against this important yet neglected disease.
Data capture method | Experiment |
---|---|
Date (Date published in a 3rd party system) | 22 October 2018 |
Language(s) of written materials | English |
Data Creators | Giuliani, S, Silva, AC, Borba, Joyce V. V. B., Ramos, PIP, Paveley, RA, Muratov, EN, Andrade, CH and Furnham, N |
---|---|
LSHTM Faculty/Department | Faculty of Infectious and Tropical Diseases > Dept of Pathogen Molecular Biology |
Participating Institutions | London School of Hygiene & Tropical Medicine, London, United Kingdom |
Date Deposited | 29 Oct 2018 14:31 |
---|---|
Last Modified | 09 Jul 2021 11:22 |
Publisher | PLOS Computational Biology |